{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:26:20Z","timestamp":1789248380334,"version":"build-2803163510"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"2","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2016,3,4]]},"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>This study compared the efficacy and safety of once-daily umeclidinium 62.5\u2005\u00b5g with once-daily glycopyrronium 50\u2005\u00b5g in patients with moderate-to-severe chronic obstructive pulmonary disease.<\/jats:p><jats:p>This was a 12-week, multicentre, randomised, open-label, parallel-group study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/Clinicaltrials.gov\/\" ext-link-type=\"uri\">Clinicaltrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02236611\">NCT02236611<\/jats:ext-link>). Patients were randomised 1:1 to umeclidinium 62.5\u2005\u00b5g or glycopyrronium 50 \u00b5g administered<jats:italic>via<\/jats:italic>Ellipta or Breezhaler dry powder inhaler, respectively. The primary endpoint was trough forced expiratory volume in 1\u2005s (FEV<jats:sub>1<\/jats:sub>) at day 85 in the per-protocol population. Other endpoints included: weighted mean FEV<jats:sub>1<\/jats:sub>over 0\u201324\u2005h and patient-reported outcomes (transition dyspnoea index score and St George's Respiratory Questionnaire total score). Adverse events were also assessed.<\/jats:p><jats:p>A total of 1037 patients were randomised to treatment. Umeclidinium was non-inferior (margin: \u221250\u2005mL) to glycopyrronium (trough FEV<jats:sub>1<\/jats:sub>at day 85 treatment difference: 24\u2005mL, 95% confidence intervals: \u22125\u201354). Improvements in other endpoints were similar between treatments. Adverse event incidences were similar for umeclidinium (37%) and glycopyrronium (36%).<\/jats:p><jats:p>Once-daily umeclidinium was non-inferior to once-daily glycopyrronium in patients with chronic obstructive pulmonary disease in trough FEV<jats:sub>1<\/jats:sub>at day 85. Patient-reported outcomes and safety profiles were similar for both treatments.<\/jats:p>","DOI":"10.1183\/23120541.00101-2015","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T01:03:23Z","timestamp":1461891803000},"page":"00101-2015","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A randomised, open-label study of umeclidinium<i>versus<\/i>glycopyrronium in patients with COPD"],"prefix":"10.1183","volume":"2","author":[{"given":"Tara","family":"Rheault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Khindri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Vahdati-Bolouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"key":"2024101706475758000_2.2.00101-2015.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org\/ Date last updated: 2015. Date last accessed: August 10, 2015."},{"key":"2024101706475758000_2.2.00101-2015.2","unstructured":"Boehringer-Ingelheim. SPIRIVA. Prescribing Information. http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Spiriva\/Spiriva.pdf Date last updated: 2014. Date last accessed: September 3, 2015."},{"key":"2024101706475758000_2.2.00101-2015.3","unstructured":"Novartis. Seebri Breezhaler. Summary of product characteristics. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002430\/WC500133769.pdf Date last updated: 2015. Date last accessed: September 5, 2015."},{"key":"2024101706475758000_2.2.00101-2015.4","unstructured":"Novartis. Seebri Neohaler. Prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207923lbl.pdf Date last updated: 2015. Date last accessed: November 6, 2015."},{"key":"2024101706475758000_2.2.00101-2015.5","unstructured":"GlaxoSmithKline. INCRUSE. Summary of product characteristics. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002809\/human_med_001755.jsp&mid=WC0b01ac058001d124 Date last updated: 2015. Date last accessed: September 3, 2015."},{"key":"2024101706475758000_2.2.00101-2015.6","unstructured":"GlaxoSmithKline. INCRUSE. Prescribing information. www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Incruse_Ellipta\/pdf\/INCRUSE-ELLIPTA-PI-PIL.PDF Date last updated: 2014. Date last accessed: September 3, 2015."},{"key":"2024101706475758000_2.2.00101-2015.7","unstructured":"AstraZeneca. Eklira Genuair. Summary of product characteristics. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002211\/WC500132661.pdf Date last updated: 2015. Date last accessed: September 9, 2015."},{"key":"2024101706475758000_2.2.00101-2015.8","unstructured":"Almirall. Tudorza Pressair. Prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202450s000lbl.pdf Date last updated: 2012. Date last accessed: October 28, 2015."},{"key":"2024101706475758000_2.2.00101-2015.9","unstructured":"Boehringer-Ingelheim. SPIRIVA. Summary of product characteristics. www.medicines.org.uk\/emc\/medicine\/20134l. Date last updated: 2014. Date last accessed: October 29, 2015."},{"key":"2024101706475758000_2.2.00101-2015.10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-4"},{"key":"2024101706475758000_2.2.00101-2015.11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/17476348.2015.996133","article-title":"Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease","volume":"9","author":"Riario-Sforza","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"2024101706475758000_2.2.00101-2015.12","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-100"},{"key":"2024101706475758000_2.2.00101-2015.13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101706475758000_2.2.00101-2015.14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/COPD.S92412","article-title":"Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis","volume":"10","author":"Ismaila","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101706475758000_2.2.00101-2015.15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/17476348.2014.962519","article-title":"Umeclidinium for the treatment of chronic obstructive pulmonary disease","volume":"8","author":"Segreti","year":"2014","journal-title":"Expert Rev Respir Med"},{"key":"2024101706475758000_2.2.00101-2015.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.03.012"},{"key":"2024101706475758000_2.2.00101-2015.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00033213"},{"key":"2024101706475758000_2.2.00101-2015.18","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-156"},{"key":"2024101706475758000_2.2.00101-2015.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.10.021"},{"key":"2024101706475758000_2.2.00101-2015.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040712"},{"key":"2024101706475758000_2.2.00101-2015.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00014304"},{"key":"2024101706475758000_2.2.00101-2015.22","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050666"},{"key":"2024101706475758000_2.2.00101-2015.23","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"2024101706475758000_2.2.00101-2015.24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70001-3"},{"key":"2024101706475758000_2.2.00101-2015.25","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200053377"},{"key":"2024101706475758000_2.2.00101-2015.26","doi-asserted-by":"publisher","DOI":"10.1186\/CVM-1-1-019"},{"key":"2024101706475758000_2.2.00101-2015.27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.402"},{"key":"2024101706475758000_2.2.00101-2015.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00589-9"},{"key":"2024101706475758000_2.2.00101-2015.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00068503a"},{"key":"2024101706475758000_2.2.00101-2015.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2024101706475758000_2.2.00101-2015.31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2466-14-118","article-title":"Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease","volume":"14","author":"Rennard","year":"2014","journal-title":"BMC Pulm Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00101-2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:52:29Z","timestamp":1740372749000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00101-2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,28]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1183\/23120541.00101-2015"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00101-2015","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}